A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Inclusion Criteria

• Female participants, 18 years or older
• Measurable disease per radiographic evaluation
• Performance status 0 or 1
• Available archival tissue sample (within 2 years) or a fresh tumor biopsy may be required
• Adequate organ, cardiac, and bone marrow function
• Dose escalation
• Participants with breast cancer:
• Locally advanced or metastatic triple negative breast cancer (ER-negative, PgR-negative, and HER2-negative according to ASCO/CAP guidelines) with disease progression
• No available alternative or curative therapy
• Participants may have received any number of prior therapies for advanced/recurrent and progressive disease
• Participants with ovarian cancer:
• Locally advanced or metastatic ovarian cancer with disease progression
• No available alternative or curative therapy
• Participants may have received any number of prior therapies for advanced/recurrent and progressive disease
• Dose expansion
• Participants with breast cancer:
• Locally advanced or metastatic triple negative breast cancer (ER-negative, PgR-negative, and HER2-negative according to ASCO/CAP guidelines)
• Disease progression after no more than 3 prior lines of therapy
• Participants with ovarian cancer:
• Locally advanced or metastatic ovarian cancer that is platinum-resistant
• Disease progression after no more than 3 prior lines of therapy

Exclusion Criteria

• Received a live, attenuated vaccine within 4 weeks prior to first study treatment
• Prior anticancer treatment including approved agents, systemic radiotherapy, or investigational therapy within 4 weeks prior first study treatment
• Cancer other than the disease under study within 2 years prior to study entry, except for some cancers with a low risk of spreading like non-melanoma skin cancers
• Inability to swallow oral medications
• Participant is breastfeeding, pregnant, or expects to become pregnant during the study
• Active autoimmune disease or documented history of autoimmune disease within 2 years prior to first study treatment
• History of peptic ulcer or stomach bleeding within 6 months prior to first study treatment
• Use of drugs contraindicated by the protocol within 4 weeks prior to and during study treatment
• Prior treatment with drugs that suppress the immune system within 2 weeks prior to first study treatment
• Presence of metastases in the brain or cancer spreading into the cerebrospinal fluid
• CSF (leptomeningeal disease)
• HIV, Hepatitis B, and C test results negative prior to first study treatment
• Major surgery within 4 weeks prior to first study treatment
• Participants who have previously received maximum cumulative lifetime anthracycline dosage or baseline ejection fraction <50% (on heart echography)